Gink­go Bioworks ac­quires strug­gling syn­bio ri­val Zymer­gen in $300M all-stock deal

Gink­go Bioworks is pick­ing up a syn­thet­ic bi­ol­o­gy com­peti­tor in what it says is its largest M&A deal yet.

Gink­go put out word ear­ly Mon­day it is ac­quir­ing Zymer­gen in an all-stock deal, valu­ing the Emeryville, CA-based syn­thet­ic bi­ol­o­gy biotech at around $300 mil­lion. The deal has been ap­proved by both com­pa­nies’ board of di­rec­tors, and is slat­ed to close some­time in the first quar­ter next year. Once done, Zymer­gen share­hold­ers will own ap­prox­i­mate­ly 5.25% of the com­bined com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER